This multicenter, prospective, double-blind study compared the safety and efficacy of clindamycin and ciprofloxacin versus ceftriaxone and doxycycline in the treatment of outpatients with mild to moderate pelvic inflammatory disease (PID) diagnosed by laparoscopy. Samples taken from the endocervix, endometrium, and abdominal cavity before treatment and from the endocervix after treatment were cultured for aerobes, anaerobes, Neisseria gonorrhoeae, and Chlamydia trachomatis. Of the 138 patients enrolled, 131 were evaluable for efficacy. The most prevalent bacteria were streptococci, staphylococci, and Escherichia coli (among aerobes) and Bacteroides species and peptostreptococci (among anaerobes). N. gonorrhoeae was present in 2% (3) of the 131 evaluable patients, and C. trachomatis was in 11% (15). The clinical cure rate was 97% (65 of 67) in the clindamycin and ciprofloxacin group and 95% (61 of 64) in the ceftriaxone and doxycycline group. Side effects were similar in both groups. In conclusion, the two regimens for the outpatient treatment of mild to moderate PID were similarly effective and safe. 
400 mg (b.i.d. for 14 days) [16] . We used a 600-mg t.i.d. dosage of clindamycin on the basis of information that this dosage is bioequivalent to 450 mg t.i.d. [17] . The Cmin is 0.69 • g/mL, which exceeds the MIC of susceptible pathogens, with the exception of C. trachomatis. However, the dosage of 450 mg q.i.d. has proved to be highly effective in the antenatal treatment of female C. trachomatis infections [18] as well as chlamydial cervicitis [19] .
Ciprofloxacin was used instead of ofloxacin because at the time the study was designed ofloxacin was not available in some of the countries in which this study was conducted. The ciprofloxacin dosage was based on the information that an oral dosage of 500 mg concentrates in the gynecologic tissue at concentrations that exceed the MICs of most of the susceptible pathogens [20] .
The primary objective of this study was to evaluate the relative efficacy and safety of the outpatient treatment of mild to moderate PID with oral clindamycin and ciprofloxacin vs. ceftriaxone and doxycycline. The secondary objective was to identify etiologic agents of PID through microbiological examinations of laparoscopic samples.
Materials and Methods
Population. This randomized, double-blind, comparative study was conducted in Chile (one center), Peru (two centers), Colombia (two centers), and Mexico (one center). Outpatients who fulfilled selection criteria were randomly assigned to one of two treatment groups. Investigators evaluated the two treatment groups according to clinical and microbiological responses. Evaluation of response was based on clinical improvement (abatement of symptoms) and the results of bacteriological cultures.
Eligible patients included those whose clinical diagnosis was mild or moderate PID, as confirmed by laparoscopy. The grading of mild or moderate PID was done according to the methods of Hager et al. [21] and Soper [22] . Patients were females between 18 and 55 years of age.
Patients were excluded if they had any observable pelvic mass; presented with laparoscopic evidence of severe PID; were pregnant or breastfeeding; were allergic to clindamycin, ciprofloxacin, ceftriaxone, or doxycycline; required other antibiotic therapy for non-protocol reasons; had had pelvic or abdominal surgery in the 30 days prior to admission (except emergency exploratory laparoscopy resulting in a primary diagnosis of PID that did not require pelvic cleanup); had concomitant disease that could have affected the evaluation of response to protocol therapy (such as inflammatory bowel disease or significant renal or hepatic disease); had a history of colitis; were known to have frequent sexual contacts with multiple partners; were seropositive for syphilis; had severe medical condition(s) (e.g., neoplasms or hematologic malignancy); had taken two or more antibiotics within 72 hours before evaluation for enrollment in the study; had received any investigational drug 30 days before evaluation for enrollment; or had been previously enrolled in the study. All patients had to sign an informed-consent form.
The following parameters were used to assess the symptomatology of PID: lower abdominal and adnexal tenderness; pain or cervical and uterine motion tenderness; presence of gramnegative intracellular diplococci in endocervical smear; temperature of >38°C; and a WBC count of > 10,000/mm [3] . Laparoscopic examination included diagnosis by physical appearance, grading of PID, evaluation of the gynecologic tract, and collection of a sample from the intraperitoneal liquid. The sample was cultured for C. trachomatis, N. gonorrhoeae, anaerobes, and aerobes. If there was no intraperitoneal liquid, a sample for culturing was obtained via lavage with a 0.9% sterile saline solution. If necessary, a second puncture was made to obtain samples for culturing.
All eligible patients were randomized to one of the following treatment groups: (1) clindamycin (300 mg, two capsules t.i.d.) and ciprofloxacin (250. mg, one tablet b.i.d.) for 14 days and placebo im (for an equivalent of one dose of ceftriaxone) or (2) ceftriaxone (250 mg im, as a single dose) and doxycycline (100 mg, one capsule b.i.d.) and placebo (two capsules t.i.d. for equivalent doses of clindamycin) for 14 days. Placebo medication was added as necessary to complete the double-blind design. All oral medication was encapsulated to ensure blinding. Use of additional antibiotics, analgesics, or antiinflammatory agents, except for acetaminophen, was not permitted during the study. The dosage and frequency of all concomitant medications were recorded.
All patients with an IUD had to have the device removed before initiation of treatment. For the duration of the study, patients were asked to practice abstinence or have their partner use a condom if they engaged in sexual intercourse.
Efficacy evaluation. Patients were evaluated on days 0 (pretreatment), 3, 7, and 16-18 (end of treatment). The following parameters were evaluated: temperature and clinical symptoms; abdominal tenderness and/or rebound; presence of abdominal mass; adnexal tenderness (right and left side); cervical motion tenderness; and presence/absence of cervical or vaginal discharge.
Global evaluation, conducted at the end of treatment (days [16] [17] [18] , included clinical assessment of a patient's condition (cure, improvement, or failure) and microbiological assessment of an endocervical sample (cure, failure, or superinfection). Clinical cure was defined by the absence of or minimal pelvic tenderness, a temperature of <37.5°C, and a WBC count of 10,000/mm [3] , if a minimum of 4 days of treatment had been completed. Clinical improvement was defined as resolution of two of the three symptoms mentioned above.
Therapy was considered a failure when one of the following circumstances was noted after at least 48 hours of protocol therapy: signs and symptoms remained unchanged or worsened (during the first 72 hours of therapy); some signs and symptoms initially abated but later worsened or failed to dissipate further; additional antibiotic therapy was required to treat the PID; pelvic surgery was required because of deteriorating status; or protocol therapy was required for > 14 days.
Microbiological cure was defined as eradication of N. gonorrhoeae and/or C. trachomatis from clinically cured patients. Failure was defined as persistence of one or both of these two organisms or, in the case of clinical improvement or failure, the presence of endocervical pathogens. Superinfection was defined as the isolation of one or more new pathogens.
A patient was considered nonevaluable for the category of clinical failure when she had received <48 hours of protocol therapy for reasons other than side effects. A patient was considered nonevaluable for the category of clinical cure when she had received <4 days of protocol therapy; required additional antibiotic therapy for non-protocol-related infections; or was infected with pathogens resistant to either of the treatment regimen drugs. Patients infected with resistant pathogens were dropped from the trial when susceptibility results were reported; further treatments were administered by a nonstudy investigator.
Patients whose therapy failed, who withdrew from the study, who had side effects that resulted in treatment failure, or who presented with superinfection during days 16-18 were followed up by a nonstudy (unblinded) physician until the condition resolved.
Laboratory tests. Routine laboratory testing was conducted on day 0 (pretreatment) and day 16-18 (end of treatment). This included a complete blood cell count with differential; determination of creatinine, glucose, aspartate aminotransferase, and alanine aminotransferase levels; urinalysis; serological tests for syphilis (Venereal Disease Research Laboratory test or rapid plasma reagin test; in positive cases, a fluorescent treponemal antibody assay was done); serum pregnancy test; and a pelvic sonogram (within 72 hours of enrollment). Endocervical specimens were obtained with a cytobrush (MRD, Camarillo, CA); endometrial specimens were obtained with a Pipelle endometrial suction curette (Dipipelle DeComier, Unimar, Wilton, CT) following laparoscopy; for culturing for N gonorrhoeae and C. trachomatis, specimens were collected with a cytobrush.
Aerobic and anaerobic bacteria were sought in the endometrial sample. Cultures for N. gonorrhoeae were performed according to the modified Thayer-Martin method. Samples for anaerobe cultures were collected in the Vacutainer Anaerobic Specimen Collector (Becton Dickinson, Lomas de Chapultepec, Mexico) and cultured in the Gaspak Plus (BBL) system (Becton Dickinson) with use of the OXOID system (Unipath Ltd., Basingstoke, Hants, England) to provide a carbon dioxide environment.
C. trachomatis was sought by the rapid chlamydia enzyme test (Test pack Chlamydiazyme, Abbott Laboratories, Chicago) for direct detection and by culture of specimens from the endocervix. At each study site, all specimens obtained for isolation of C. trachomatis were cultured in cycloheximide-treated McCoy cells in 96-well micro-titer plates [23] . Specimens were also stored at -70°C for transport to a central laboratory in Seattle. At the central laboratory, cultures were done as previously described.
At the end of treatment (day [16] [17] [18] , culture specimens of the endocervix and urethra were taken only from those patients whose pretreatment cultures were positive for N gonorrhoeae. For patients who were positive for C. trachomatis at baseline, rapid tests were done and cultures of endocervical samples were done. At the follow-up visit (day [28] [29] [30] [31] [32] [33] [34] [35] , rapid tests were done and culture specimens were taken again from the endocervix of patients who had been positive at baseline for C. trachomatis. Only patients whose cultures were positive were considered for microbiological evaluation. However, patients from whom no pathogen was isolated prior to treatment were not excluded from clinical-efficacy evaluation.
Side effects. All side effects that occurred in subjects during their participation in this study (from enrollment through final clinic visit) were recorded. In addition, any known event that occurred subsequent to this study period that the investigator assessed as possibly related to the investigational medication was also reported. Side-effect-related failures were those cases in which patients withdrew from the study because of side effects.
Statistical analysis. The continuous variables were analyzed with use of the one-factor analysis of variance (ANOVA) model at day 0 (pretreatment) and with the twofactor ANOVA model (with treatment group and investigator as independent fixed factors) at days 3, 7, and 16-18 (end of treatment). The equality of treatment means was assessed by means of the F test. The treatment effect was considered significant for P values of and marginally significant for P values of and >.05.
Ordinal categorical variables with five or more categories were treated as continuous and analyzed as such. The remaining categorical variables were analyzed by the x2 test for homogeneity of proportions. All statistical tests performed were two-sided. All analyses and graphics were produced with the SAS statistical package (SAS, version 6.08; SAS Institute, Cary, NC).
Baseline and efficacy variables were analyzed for evaluable patients. To assess the influence of the nonevaluable patients on the results, selected variables were also analyzed for all enrolled patients. The safety data were evaluated for all enrolled patients.
Results
Laparoscopic examination. A total of 176 patients presented with symptoms of PID and underwent laparoscopy. Of these 176, 139 (79%) of the patients were confirmed to NOTE. Cm = clindamycin; Cpfx = ciprofloxacin; Ctri = ceftriaxone; Dox = doxycycline; IUD = intrauterine contraceptive device; STD = sexually transmitted disease.
have PID. The main differential-diagnostic errors accounting for false-positive findings in patients with PID symptoms involved normal pelvic examination (n = 8), acute appendicitis (n = 4), endometriosis (n = 6), benign ovarian tumors (n = 6), unspecified pelvic pain (n = 3), and ectopic pregnancy (n = 3).
Patient population and demographics. A total of 138 patients met all subject-selection criteria and were enrolled in the study; 69 were randomized to each treatment group. One patient who underwent laparoscopy and had PID was not enrolled in the study because of previous antibiotic treatment. All of the 138 eligible patients received some study medication and were evaluable for safety. Ninety-five percent (131) of the 138 patients completed the study and were evaluable for efficacy (97% [67 of 69] in the clindamycin and ciprofloxacin group and 93% [64 of 69] in the ceftriaxone and doxycycline group).
All of the patients who discontinued treatment in the two groups were also nonevaluable. In the clindamycin and ciprofloxacin group, one patient chose to discontinue because she was asymptomatic and another withdrew because of a side effect. Both of these patients were nonevaluable because they missed their final visit. In the ceftriaxone and doxycycline group, one patient withdrew because of a side effect, one was lost to follow-up, and one was withdrawn because of receiving additional antibiotic treatment for syphilis after initiation of study medication. These three patients were nonevaluable because they missed their final visit.
One patient was ineligible after starting to receive study medication because she received two doses of gentamicin before the laparoscopy at the time of screening. This patient was nonevaluable because she received study medication for <2 days. One more patient from the ceftriaxone and doxycycline group completed the study but was nonevaluable because her syphilis test was reactive during screening.
Of the 138 patients who enrolled, 134 (97%) were Hispanic; the mean age was 29.8 years. There were no statistically significant differences between the two groups in terms of race, age, height, and weight.
Medical history and physical examination. The two treatment groups were similar in terms of medical and surgical histories. Analysis showed no statistically significant differences at the P = .05 level between treatment groups with respect to reproductive history (gravida, abortus, para), previous episodes of PID, or history of sexually transmitted disease (STD). For contraception, most patients used an IUD or nothing. There were no differences between the treatment groups in terms of history of IUD usage or the number of patients who were using an IUD at the time of diagnosis (table 1).
Most of the enrolled patients in both treatment groups reported several symptoms during the pelvic examination; adnexal tenderness (136/138), cervical motion tenderness (131/138), abdominal tenderness (120/138), and vaginal/cervical discharge (123/138). There were no important differences between the two treatment groups with respect to any of these physical findings.
In the clindamycin and ciprofloxacin group, 49 of the 69 patients (71%) had mild PID and 20 (29%) had moderate PID. Of the 69 patients in the ceftriaxone and doxycycline group, 45 (65%) had mild PID and 24 (35%) had moderate PID. General characteristics of the patients in the two treatment groups are provided in table 1.
Center-by-center analysis of characteristics at enrollment.
Center-by-center analyses were carried out comparing pretreatment patient characteristics. There were six centers; data from two were combined for the analysis because of low enrollment. Refer to table 2 for the numbers enrolled in each treatment group at all of the centers. The variables analyzed were age, NOTE. Cm = clindamycin; Cpfx = ciprofloxacin; Ctri = ceftriaxone; Dox = doxycycline. * Oyarzim and Paz's data were combined for center-by-center analysis because of low enrollment. NOTE. P = .552 with respect to clinical evaluations between the two treatment groups (x2 test). Cm = clindamycin; Cpfx = ciprofloxacin; Ctri = ceftriaxone; Dox = doxycycline. race, height, weight, medical and surgical histories, and menstrual and reproductive histories. No significant differences were seen between the centers for any one of these variables.
Efficacy. There were 131 patients who met criteria for the evaluation of efficacy: 67 in the clindamycin and ciprofloxacin group and 64 in the ceftriaxone and doxycycline group. Evaluable patients were those whose syphilis test was nonreactive or weakly reactive, who were evaluated at least on day 0 (pretreatment) and day 16-18 (end of treatment), and who were treated with the study medication for at least 2 days. The primary efficacy measure was clinical evaluation, and the secondary efficacy measure was microbiological evaluation.
Clinical evaluations. The clinical outcome was assessed as cure, improvement, or failure on the global clinical-response evaluation form, in accordance with the criteria cited in Methods. Eighty-five percent (57) of the 67 evaluable patients in the clindamycin and ciprofloxacin group and 77% (49) of the 64 evaluable patients in the ceftriaxone and doxycycline group were categorized as cured. The improvement category included 12% (8) of the 67 evaluable patients in the clindamycin and ciprofloxacin group and 18% (12) of the 64 evaluable patients in the ceftriaxone and doxycycline group. Only 3% (2 of 67) and 5% (3 of 64) of the patients in these respective groups were categorized as treatment failures. There was no statistically significant difference between the two treatment groups with respect to clinical evaluations (table 3) .
Microbiology. The number of aerobic and anaerobic organisms isolated from patients' endocervix, endometrium, and laparoscopic specimens before treatment are shown in table 4. Of the 138 samples obtained by laparoscopy, 87 (63%) were sterile (45 from clindamycin and ciprofloxacin recipients and 42 from ceftriaxone and doxycycline recipients). The number of patients whose pretreatment cultures were monomicrobic vs. polymicrobic is shown in table 5. In both treatment groups, more samples taken from the endocervix were polymicrobic than monomicrobic; the numbers of polymicrobic and monomicrobic samples taken from the endometrium and by laparoscopy were similar.
The numbers of evaluable patients whose cultures were positive for N. gonorrhoeae and C. trachomatis before treatment and on day 16-18 (end of treatment) or at the final visit are shown in table 6. Of the two patients in the clindamycin and ciprofloxacin group infected with N. gonorrhoeae, one was culture-negative at the end of treatment and the other remained positive. All the patients whose cultures were positive at baseline for C. trachomatis were negative at the end of treatment.
All of the patients who tested positive for N. gonorrhoeae and C. trachomatis at baseline in the ceftriaxone and doxycycline group tested negative at the end of treatment.
Isolates cultured from samples of patients whose clinical assessment was categorized as improvement or failure are shown in table 7. Of those patients with incomplete responses, there were eight whose cultures were polymicrobic and two whose cultures were monomicrobic in the clindamycin and ciprofloxacin group; in the ceftriaxone and doxycycline group, there were 10 patients whose cultures were polymicrobic and five whose cultures were monomicrobic.
Adverse effects. Systolic and diastolic blood pressures were normal at baseline and after treatment in both treatment groups. However, the systolic pressure in the ceftriaxone and doxycycline group was higher than the systolic pressure in the clindamycin and ciprofloxacin group at baseline and remained higher throughout treatment. Pulse rates, respiration rates, and oral temperatures were normal at baseline and remained unchanged throughout treatment. There were no differences in these variables between the two treatment groups.
During treatment, WBC counts were recorded only on day 16-18. There were six patients (three in each group) whose WBC count was > 10,000/mm3 . There was no significant difference between the groups in terms of WBC counts. No other laboratory values were significantly different between the groups at baseline and at the end of treatment. Eight-three percent (57) of the 69 patients enrolled in the clindamycin and ciprofloxacin group and 75% (52) of the 69 patients enrolled in the ceftriaxone and doxycycline group reported at least one side effect.
The most commonly occurring side effects reported (unrelated to PID) were nausea, vomiting, diarrhea, and headache. Of those events considered to be drug-related, there were 11 reports of nausea, 5 of vomiting, and 16 of diarrhea in the clindamycin and ciprofloxacin group; in the ceftriaxone and doxycycline group, there were 27 reports of nausea, 18 of vomiting, and 1 of diarrhea.
Two patients withdrew from the study because of side effects; one patient in the clindamycin and ciprofloxacin group experienced a moderate rash, and one patient in the ceftriaxone and doxycycline group experienced severe pruritus and moderate rash. These side effects were considered drug-related.
Discussion
For many years, the traditional view of acute PID was that its clinical characteristics were fairly uniform and definable on the basis of history, physical examination, and common laboratory tests [24] . However, the systematic use of laparoscopy for the diagnosis of this type of infection resulted in a considerably revised view of both the clinical manifestations of acute PID and the problems of differential diagnosis. Clinical diagnostic accuracy has generally been found to be lower than 65%, and even as low as -50% in some studies [25] [26] [27] [28] [29] [30] [31] [32] . Using laparoscopy as the "gold standard" in our series (the first study, to our knowledge, done in Latin America with this methodology), we found that the clinical diagnosis had an accuracy of 79% (139 of 176 patients), with values from different centers ranging from 60% to 90%. There is no clear evidence as to why 63% of the laparoscopic samples were sterile. The high percentage may have been due to an inadequate number of samplings or the techniques used in the collection, handling, and/or processing of the samples.
The main differential diagnostic errors involved acute appendicitis, pelvic endometriosis, tubo-ovarian abscess, and intra- NOTE. Cm = clindamycin; Cpfx = ciprofloxacin; Ctri = ceftriaxine; Dox = doxycycline; PID = pelvic inflammatory disease.
pelvic bleeding because of various causes, similar to findings in other series [24] . In using the grading criteria proposed by Hager et al. [21] , we found that several clinical features of PID, particularly adnexal tenderness, were present in most cases. However, temperature of >38°C, which is considered one of the classical clinical criteria of acute PID [24] , was present in only 5% (six) of the 131 evaluable patients. One reason for this discrepancy is that these data concern patients with mild to moderate PID, whereas other series were of cases of more severe PID.
Unlike studies of severe PID, in which a large number of parenteral antibiotics have been tested (for a review, see Walker et al. [33] ), few comparative studies have been performed of mild to moderate outpatient-treated PID. This multicenter comparative clinical trial is the first comparing the two primary combination antimicrobial regimens most recently recommended by the CDC for the outpatient treatment of PID [16] .
The efficacy of the two regimens was almost identical. No differences in any clinical and/or laboratory parameters were detected. The failure rate for clindamycin and ciprofloxacin was 3%, and that for ceftriaxone and doxycycline was 5%, with no statistically significant difference between the two groups; the rate of microbiological cure of STD was similar for both. Although all regimens were successful in curing the acute signs and symptoms of PID, their long-term impact on sequelae such as infertility, ectopic pregnancy, and pain is unknown.
The present study confirms that PID is a mixed infection caused by aerobes, anaerobes, and sexually transmitted pathogens (N gonorrhoeae and C. trachomatis) [6, 13] . The most common organisms in our series were streptococci, staphylococci, Escherichia coli, Klebsiella species, and Gardnerella species (among aerobes) and peptostreptococci and Bacteroides species (among anaerobes). There were similar numbers of polymicrobic and monomicrobic specimens collected within and between the two treatment groups. The most commonly occurring organisms in patients who had incomplete clinical responses were streptococci, peptostreptococci, lactobacilli, Gardnerella species, and staphylococci; there was no predominant single organism or polymicrobic group identified among isolates.
Although there were more polymicrobic than monomicrobic specimens, the significance of this is difficult to interpret because of the small number of patients in both treatment groups whose response was incomplete. A surprising finding was the low incidence of N. gonorrhoeae (2%; 3 of 131) and C. trachomatis (11%; 15 of 131) in our patients. Previous studies have demonstrated a considerable range in the proportion of patients with PID who are culture-positive for N. gonorrhoeae or C. trachomatis, but N. gonorrhoeae usually is present in 5% to 26% of the patients with acute PID (for a review, see Hillier et al. [34] ), and C. trachomatis has been identified in 36% to 50% of the women with PID [3, 9, 35] .
Reasons for the low incidence of both STD pathogens are unclear. One could be the low number of sex partners in our population. Both racial/ethnic variations and geographic variations in the prevalence of STD pathogens in women with PID have been described in other series. However, we cannot compare those series against a Latin American population because no reports have been published on the incidence of STD in that region.
Another reason for the low incidence of these two pathogens in our series could have been technical faults in transportation or culture of the specimens. However, N. gonorrhoeae has been cultured for many years in all laboratories involved in the present study. With regard to C. trachomatis, all samples were sent to a central reference laboratory in Seattle for culture; the control enclosed with each delivery ensured the quality of the transported samples, and in every batch transported to the central laboratory there were positive samples.
As expected, the most commonly reported side effects were nausea, vomiting, diarrhea, and headaches. Patients in the clin- damycin and ciprofloxacin group had a higher incidence of diarrhea, whereas patients in the ceftriaxone and doxycycline group had a higher incidence of nausea and vomiting. No cases of pseudomembranous colitis were reported. Side effects seen in both groups were mild to moderate and were well tolerated by the patients. It is worth mentioning that no patient in this study had to stop treatment because of gastrointestinal side effects.
